肝線維症治療薬市場：薬剤タイプ別、流通チャネル別-2024-2030年の世界予測

肝線維症治療薬市場規模は2023年に142億8,000万米ドルと推定され、2024年には155億7,000万米ドルに達し、CAGR 9.74％で2030年には273億8,000万米ドルに達すると予測されています。

肝線維症治療薬は、肝線維化のプロセスを予防、停止、または逆転させるように設計された医薬品です。肝線維症は、コラーゲンを含む細胞外マトリックスタンパク質の過剰蓄積を特徴とする病態であり、肝組織の瘢痕化をもたらします。この状態を放置すると、肝硬変や肝がんなど、より重篤な肝疾患へと進行する可能性があります。これらの薬剤は、線維化プロセスを破壊し、炎症を緩和し、肝機能を改善することを目的としています。B型肝炎やC型肝炎、非アルコール性脂肪性肝炎（NASH）、アルコール性肝疾患などの罹患率が上昇していることから、肝線維症治療薬を含む効果的な治療法の必要性が高まっています。新規治療薬開発のための製薬会社や研究機関による投資の増加は、肝線維症治療薬の開発を拡大しています。肝線維症治療薬の開発・生産コストが高いことが市場成長の妨げとなっています。肝疾患と闘い、肝臓の健康を促進することを目的とした国際的なヘルスケアプログラムが利用可能であり、肝線維症の研究と医薬品開発に対する認識と資金が増加していることが、市場成長の機会を生み出すと期待されています。

薬剤の種類線維化を予防・抑制する抗線維化剤の使用拡大

抗線維化剤は、肝臓における線維化（瘢痕化）の形成を予防・軽減するために特別に設計された薬剤です。これらの薬剤は、細胞外マトリックスタンパク質の蓄積に関与する経路を標的とすることによって作用し、それによって線維化プロセスを遅らせたり、逆転させたりします。これらの薬剤は肝線維化を引き起こす疾患の管理に不可欠であり、肝硬変や肝不全への進行を食い止める可能性を提供します。抗酸化炎症調節薬は、肝臓内の酸化ストレスと炎症経路に作用する薬剤です。酸化ストレスと炎症は肝線維化の主要な促進因子であり、肝障害の進行に寄与します。これらの経路を調節することで、これらの薬剤は肝臓をさらなる損傷から守り、線維化のプロセスを阻止し、場合によっては既存の線維化の消失を促進することを目的としています。抗ウイルス薬は、特にB型肝炎やC型肝炎などのウイルス感染によって線維化が引き起こされた場合に、肝線維症の管理において重要な役割を果たします。ウイルス感染を効果的に制御または駆除することにより、これらの薬剤は線維化を誘発する継続的な肝障害を予防し、肝硬変や肝がんを含む重篤な肝疾患の発症リスクを低減します。免疫調節薬は、免疫系の反応に影響を及ぼし、肝線維症の発症と進行に寄与する薬剤です。これらの薬剤は、免疫反応の特定の成分を増強または抑制することができ、肝臓における炎症および線維化活性を低下させることを目的としています。その正確な役割は、線維化の根本的な原因によって異なるため、標的治療戦略の重要な要素となっています。

流通チャネルオンライン薬局の24時間365日サービスによる肝線維症治療薬へのアクセスの向上

オフライン薬局は肝線維症治療薬の基本的な流通チャネルを構成しています。これらの薬局は、地域社会内またはその近くに位置し、患者が簡単にアクセスできるようになっています。独立系薬局やチェーン薬局を含むオフライン薬局は、患者一人ひとりに合わせたサービスを提供し、すぐに薬剤を入手できるため、すぐに治療を受けたい多くの患者にとって好ましい選択肢となっています。病院内薬局は、病院や臨床現場における入院患者や外来患者への調剤を専門としています。特に、直接医療を受ける患者や特定の治療が必要な患者に対して、肝線維症治療薬の配布において重要な役割を果たしています。病院薬局は、医学的管理下にある肝線維症患者の特殊なニーズに対応し、タイムリーで正確な薬剤の提供を保証します。大規模な薬局チェーンや薬局部門を持つスーパーマーケットを含む小売薬局は、医薬品へのアクセスを向上させる広範なネットワークを提供しています。小売薬局は、幅広い医薬品を提供し、幅広い層の利用を可能にしています。小売薬局は、その広範な存在感と経営効率を活用することで、流通ネットワークに大きく貢献しています。オンライン薬局は、肝線維症治療薬の成長する流通チャネルとして登場し、利便性としばしば競争力のある価格を提供しています。オンライン薬局は、薬を直接自宅に届けることを好む患者に対応しており、実店舗を訪れる必要がないです。オンライン薬局は、移動に問題のある患者や遠隔地に住む患者にとって特に有益です。

地域別インサイト

南北アメリカ、特に北米は、肝線維症治療薬の開発と採用において極めて重要な地域です。南北アメリカは、医薬品の技術革新、規制の枠組み、医療支出において重要な地域であり、肝線維症治療薬の主要市場となっています。肥満や飲酒などの要因により肝疾患の有病率が高いことが、この地域における効果的な治療法の必要性をさらに高めています。さらに、政府および民間部門からの肝疾患研究に対する強力な支援が、肝線維症に対する新規かつ先進的な治療法の開発を後押ししています。アジア太平洋地域は肝線維症治療薬市場の急成長を目の当たりにしているが、これはヘルスケア支出の増加、肝疾患に対する意識の高まり、医療インフラの改善に起因しています。日本、中国、韓国などの国々が最前線にあり、中でも日本は先進的なヘルスケアシステムと高い医薬品研究開発率により、大きな貢献をしています。この地域では、肝線維症の主要な危険因子であるB型肝炎とC型肝炎の有病率が比較的高く、効果的な治療オプションが急務となっています。さらに、拡大する中間所得層が高度な治療薬を購入できるようになっており、APACの肝線維症治療薬市場を押し上げています。EMEA地域は、肝線維症治療薬市場の多様な展望を示しています。欧州は、強力な規制の枠組み、広範なヘルスケアへのアクセス、肝臓疾患に対する高い認識を特徴としており、これらの治療法の主要市場となっています。欧州肝疾患研究協会（EASL）のイニシアチブは、肝線維症治療を取り巻く環境を強化し、研究と認知度をさらに高めています。中東の一部の国では医療インフラが整備されつつあり、肝線維症治療へのアクセスが拡大する可能性があります。アフリカの市場成長は経済的な制約によって妨げられているが、国際的な医療機関が教育や治療プログラムを通じて状況改善に乗り出しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは肝線維症治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、肝線維症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.肝線維症治療薬市場の市場規模および予測は？

2.肝線維症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.肝線維症治療薬市場の技術動向と規制枠組みは？

4.肝線維症治療薬市場における主要ベンダーの市場シェアは？

5.肝線維症治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で慢性肝疾患の罹患率が増加
    • 肝線維症の治療に対する有利な償還政策
  • 抑制要因
    • 肝線維症治療薬の策定と開発の複雑さ
  • 機会
    • 新規開発のための新たな調査資金肝線維症治療薬
    • 肝臓の画像診断技術と肝線維症のバイオマーカーの改善
  • 課題
    • 肝線維症の治療薬承認のための厳格な規制枠組み
• 市場セグメンテーション分析
  • 薬剤の種類：線維症の形成を予防および軽減するための抗線維症薬の使用が増加
  • 流通チャネル：オンライン薬局の24時間年中無休のサービスにより肝線維症治療薬へのアクセスが向上
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 肝線維症治療薬市場薬の種類別

• 抗線維化剤
• 抗酸化炎症調節剤
• 抗ウイルス薬
• 免疫調節剤

第7章 肝線維症治療薬市場：流通チャネル別

• オフライン薬局
• オンライン薬局

第8章 南北アメリカの肝線維症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の肝線維症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの肝線維症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • サーボデュタイド第2相試験では、治療を受けた成人の83%がMASHによる肝疾患で画期的な結果を達成し、線維症が大幅に改善したことが示されました。
  • イプセン、米国FDAが希少胆汁うっ滞性肝疾患の治療薬エラフィブラノールの新薬申請を優先審査に指定したことを発表
  • マドリガル・ファーマシューティカルズ、肝線維症を伴うNASHの治療薬レスメチロムの新薬申請のNDA受理と優先審査を発表
• 戦略分析と提言

第12章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. LIVER FIBROSIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. LIVER FIBROSIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. LIVER FIBROSIS DRUGS MARKET DYNAMICS
• FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 20. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 30. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 37. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 38. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 39. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 40. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 43. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 44. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 45. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 46. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 49. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 50. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 51. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 52. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 53. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 54. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 55. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 56. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 61. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 62. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 70. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 77. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 78. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 79. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 80. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 83. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 84. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 85. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 86. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 87. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 88. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 89. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 90. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 91. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 92. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 93. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 94. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 95. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 96. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 97. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 98. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 101. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 102. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 103. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 104. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 107. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 108. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 109. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 110. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 113. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 114. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 115. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 116. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 119. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 120. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 121. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 122. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 126. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 128. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 131. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 132. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 133. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 134. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 137. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 138. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 139. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 140. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 143. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 144. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 145. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 146. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 157. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 158. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 159. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 160. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 163. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 164. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 165. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 166. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 169. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 170. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 171. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 172. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 175. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 176. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 177. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 178. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 181. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 182. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 183. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 184. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 187. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 188. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 189. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 190. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 193. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 194. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 195. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 196. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 197. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 198. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 199. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 200. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 201. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 202. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 205. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 206. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 207. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 208. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 211. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 212. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 213. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 214. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 217. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 218. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 219. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 220. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 221. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 222. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 223. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 224. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 225. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 226. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 227. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 228. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 229. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 230. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 231. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 232. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 236. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 238. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 242. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 247. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 248. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 249. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 250. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 253. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 254. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 255. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 256. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 259. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 260. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 261. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 262. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 265. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 266. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 267. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 268. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 278. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 280. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
• TABLE 282. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
• TABLE 283. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 284. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

[196 Pages Report] The Liver Fibrosis Drugs Market size was estimated at USD 14.28 billion in 2023 and expected to reach USD 15.57 billion in 2024, at a CAGR 9.74% to reach USD 27.38 billion by 2030.

Liver fibrosis drugs are pharmaceutical agents designed to prevent, halt, or reverse the process of liver fibrosis. Liver fibrosis itself is a pathological condition characterized by the excessive accumulation of extracellular matrix proteins, including collagen, which leads to the scarring of liver tissue. This condition can progress to more severe forms of liver disease, such as cirrhosis and liver cancer if left untreated. These drugs aim to disrupt the fibrogenic processes, mitigate inflammation, and improve liver function. The rising incidence of conditions such as hepatitis B and C, non-alcoholic steatohepatitis (NASH), and alcoholic liver disease fuels the need for effective treatments, including liver fibrosis drugs. Rising investments by pharmaceutical companies and research institutions for developing novel therapeutics are expanding the development of liver fibrosis drugs. The high development and production costs of liver fibrosis drugs hamper the growth of the market. The availability of international healthcare programs aimed at combating liver diseases and promoting liver health with increasing awareness and funding for liver fibrosis research and drug development are expected to create opportunities for market growth.

Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis

Antifibrotic agents are specifically designed to prevent and reduce the formation of fibrosis (scarring) in the liver. These drugs work by targeting the pathways involved in the accumulation of extracellular matrix proteins, thereby slowing down or reversing the fibrotic process. They are vital in managing diseases that lead to liver fibrosis, offering a potential means to halt the progression towards cirrhosis and liver failure. Antioxidant inflammation modulators are drugs that act on the oxidative stress and inflammatory pathways within the liver. Oxidative stress and inflammation are key drivers of liver fibrosis, contributing to the progression of liver injury. By modulating these pathways, these agents aim to protect the liver from further damage, halt the fibrotic process, and, in some instances, promote the resolution of existing fibrosis. Antiviral drugs play a crucial role in the management of liver fibrosis, particularly in cases where the fibrosis is caused by viral infections such as Hepatitis B and Hepatitis C. By effectively controlling or eradicating the viral infection, these drugs prevent the ongoing liver damage that triggers fibrosis, thereby reducing the risk of developing severe liver conditions including, cirrhosis or liver cancer. Immune modulators are drugs that influence the immune system's response and contribute to the development and progression of liver fibrosis. These drugs can either enhance or suppress specific components of the immune response, aiming to reduce the inflammatory and fibrogenic activity in the liver. Their precise role varies depending on the underlying cause of fibrosis, making them a critical component of a targeted therapeutic strategy.

Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services

Offline pharmacies constitute a fundamental distribution channel for liver fibrosis drugs. They are located within or near community settings, providing easy access for patients. Offline pharmacies, including independent and chain pharmacies, offer personalized services and immediate drug availability, making them a preferred option for many patients seeking immediate treatment. Hospital pharmacies specialize in dispensing medications to inpatients and outpatients within a hospital or clinical setting. They play a critical role in the distribution of liver fibrosis drugs, especially for patients receiving direct medical care or those with specific therapeutic needs. Hospital pharmacies ensure the timely and accurate provision of medications, catering to the specialized needs of liver fibrosis patients under medical supervision. Retail pharmacies, including large pharmacy chains and supermarkets with pharmacy departments, offer extensive networks that enhance drug accessibility. They provide liver fibrosis drugs among a wide range of pharmaceutical products, ensuring availability for a broad demographic. Retail pharmacies contribute significantly to the distribution network by leveraging their extensive presence and operational efficiencies. Online pharmacies have emerged as a growing distribution channel for liver fibrosis drugs, offering convenience and often competitive pricing. They cater to patients who prefer having their medications delivered directly to their homes, eliminating the need for physical store visits. Online pharmacies are particularly beneficial for patients with mobility issues or those living in remote areas.

Regional Insights

The Americas, particularly North America, stands as a pivotal region in the development and adoption of liver fibrosis drugs. The Americas represents a significant region in pharmaceutical innovation, regulatory frameworks, and health spending, making it a primary market for liver fibrosis therapies. The high prevalence of liver diseases due to factors such as obesity and alcohol consumption further drives the need for effective treatments in this region. Additionally, strong support for liver disease research from both government and private sectors bolsters the development of new and advanced treatments for liver fibrosis. The Asia-Pacific region is witnessing rapid growth in the liver fibrosis drug market, attributed to increasing healthcare expenditure, growing awareness of liver diseases, and improving healthcare infrastructure. Countries such as Japan, China, and South Korea are at the forefront, with Japan being a significant contributor due to its advanced healthcare system and high rate of pharmaceutical R&D. The prevalence of hepatitis B and C, major risk factors for liver fibrosis, is relatively high in this region, driving the urgency for effective treatment options. Moreover, the expanding middle-class population is increasingly able to afford advanced therapies, thereby boosting the market for liver fibrosis drugs in APAC. The EMEA region presents a diverse outlook on the market for liver fibrosis drugs. Europe is characterized by its strong regulatory frameworks, widespread healthcare access, and high awareness of liver conditions, making it a major market for these therapies. Initiatives by the European Association for the Study of the Liver (EASL) further support research and awareness, enhancing the landscape for liver fibrosis treatment. Certain countries in the Middle East are witnessing growth in healthcare infrastructure, which could lead to increased access to liver fibrosis drugs. Africa's market growth is hindered by economic constraints, but international health organizations are stepping in to improve the situation through educational and treatment programs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liver Fibrosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Fibrosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Liver Fibrosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Arbutus Biopharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hepion Pharmaceuticals, Inc., Inventiva S.A., LG Life Science Ltd., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Mirum Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmaxis Limited, and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Liver Fibrosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Type
  • Antifibrotic Agents
  • Antioxidant Inflammation Modulators
  • Antiviral Drugs
  • Immune Modulators

• Distribution Channel
  • Offline Pharmacies
    • Hospital Pharmacies
    • Retail Pharmacies

• Online Pharmacies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Liver Fibrosis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Fibrosis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Liver Fibrosis Drugs Market?

4. What is the market share of the leading vendors in the Liver Fibrosis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Liver Fibrosis Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic liver diseases worldwide
    • 5.1.1.2. Favorable reimbursement policies for treatment of liver fibrosis
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity in formulation and development of liver fibrosis drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging research funding for the development of novel liver fibrosis drugs
    • 5.1.3.2. Improvements in liver imaging techniques and biomarkers for liver fibrosis
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory frameworks for drug approval of liver fibrosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
  • 5.2.2. Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Liver Fibrosis Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Antifibrotic Agents
• 6.3. Antioxidant Inflammation Modulators
• 6.4. Antiviral Drugs
• 6.5. Immune Modulators

7. Liver Fibrosis Drugs Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Offline Pharmacies
• 7.3. Online Pharmacies

8. Americas Liver Fibrosis Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Liver Fibrosis Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Liver Fibrosis Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis
  • 11.3.2. Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease
  • 11.3.3. Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
• 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

• 12.1. Key Company Profiles
• 12.2. Key Product Portfolio